Led by Caroline Huber, Associate Director of Policy and Economics, a surprising new study was recently published in The Journal of Infectious Diseases, estimating the overlooked social, economic and health impacts of the 2013-2016 West Africa Ebola crisis.
As the spotlight on manufacturers’ raising the prices of therapies already on the market shows no sign of dimming, one industry group recently unveiled its intentions to dig a little deeper into the topic. The Institute for Clinical and Economic Review (ICER) says it will create a series of so-called Unsupported Price Increase (UPI) reports that will examine whether price increases are justified.
We are pleased to announce that Precision’s Chief Scientist Dr. Jeroen Jansen will be participating in a special workshop organized by ISPOR on the topic of value assessments. The workshop, part of ISPOR’s ongoing Summit Series, will take place on Thursday, February 28th, 2019 at 12:00pm EST. Entitled Novel Approaches to Value Assessment, WITHIN the Cost-Effectiveness Framework, this webinar will feature a video presentation from Dr. Jansen as well as a live Q&A session at the conclusion with moderator Lou Garrison, PhD.
In a special commentary appearing in STAT News, Jacki Chou, Senior Director, Policy & Economics, and her co-author discuss overcoming 5 critical challenges in the US biosimilars marketplace, offering some strategic policy recommendations for the consideration of key healthcare stakeholders. […]
A Precision-led study recently published in ISPOR’s Value in Health examines whether budget impact models typically overestimate or underestimate real-world budget impact. PHE study authors Julia Snider, Jesse Sussell, Mahlet Tebeka, Alicia Gonzalez along with scientific advisor Peter Neumann focused on 6 ICER- BIM estimates—comparing each with ex-post estimates and determined that estimates of uptake were substantially higher than ex-post market-based estimates of use.